XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ...

(MENAFN- GlobeNewsWire - Nasdaq) XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing With the clinical ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing We apologize, but this video has failed to load. Try refreshing ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLOTM 1 having advanced ...

Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol. Management Acute polyarthritis was successfully managed by intravenous bolus methylprednisolone ...